TIL

Instil Bio Inc

7.45

Jul 17 • 02:02PM ET -0.06 (-0.80%)

Healthcare Biotechnology USA Micro NASD

Peers: BYSI CING ESLA IBIO IBO IMA IMMP INKT PDSB RADX

| Held by: VTI VXF IWC AVSC DFAS DFAC DFSU

Index	-
Market Cap	50.52M
Enterprise Value	61.02M
Income	-47.38M
Sales	0.00M
Book/sh	16.32
Cash/sh	11.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Mar 19, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.46
P/C	0.68
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	39.87
Current Ratio	39.87
Debt/Eq	0.77
LT Debt/Eq	0.77
Option/Short	No / Yes

EPS (ttm)	-7.08
EPS next Y	-
EPS next Q	-0.35
EPS this Y	89.07%
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	32.28% -12.70%
Sales past 3/5Y	- -
EPS Y/Y TTM	40.85%
Sales Y/Y TTM	-
EPS Q/Q	85.64%
Sales Q/Q	-
Earnings	May 15 BMO
EPS/Sales Surpr.	-5.08% -

Insider Own	40.40%
Insider Trans	0.00%
Inst Own	26.71%
Inst Trans	-4.77%
ROA	-21.64%
ROE	-37.07%
ROIC	-24.21%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.25%
SMA50	-5.36%
SMA200	-27.37%
Trades

Shs Outstand	6.78M
Shs Float	4.04M
Short Float	5.81%
Short Ratio	10.71
Short Interest	0.23M
52W High	33.83 -77.98%
52W Low	5.67 31.39%
Volatility	3.22% 3.88%
ATR (14)	0.26
RSI (14)	37.56
Beta	1.94
Rel Volume	0.41
Avg Volume	21.91K
Volume	6,388

Perf Week	-3.25%
Perf Month	-2.10%
Perf Quarter	-16.29%
Perf Half Y	3.62%
Perf YTD	-32.27%
Perf Year	-73.10%
Perf 3Y	-40.87%
Perf 5Y	-98.03%
Perf 10Y	-
Recom	3.00
Target Price	7.00
Prev Close	7.51
Price	7.45
Change	-0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-06-26	Downgrade	Robert W. Baird	Outperform → Neutral	$7
Jan-07-25	Upgrade	Jefferies	Hold → Buy	$11 → $52
Nov-04-24	Initiated	JMP Securities	Mkt Perform
Apr-12-24	Downgrade	Jefferies	Buy → Hold	$5 → $11
Nov-01-22	Downgrade	Truist	Buy → Hold	$16 → $6
Nov-01-22	Downgrade	Cowen	Outperform → Market Perform
Aug-13-21	Initiated	Robert W. Baird	Outperform	$34
Apr-13-21	Initiated	Truist	Buy	$32
Apr-13-21	Initiated	Morgan Stanley	Equal-Weight	$24
Apr-13-21	Initiated	Cowen	Outperform

Show Previous Ratings

May-15-26 07:00AM	Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-27-26 07:00AM	Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.82%
Jan-06-26 07:00AM	Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco (GlobeNewswire) -45.81%
Nov-13-25 07:00AM	Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.20%
Sep-10-25 07:00AM	Instil Bio Announces ImmuneOnco's Presentation of '2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) (GlobeNewswire) -9.81%
06:00AM	Loading…
Aug-13-25 06:00AM	Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-25 06:00AM	ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China (GlobeNewswire) -11.14%
Jul-02-25 06:00AM	Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors (GlobeNewswire) +8.57%
Jun-20-25 12:00PM	Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know (Zacks)
Jun-16-25 09:55AM	Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet (Zacks)
Jun-11-25 07:00AM	Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program (GlobeNewswire)
Jun-04-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice (Zacks) +15.05%
Jun-02-25 11:46AM	Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results (Zacks) +10.02%
07:00AM	Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
May-30-25 07:00AM	Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -11.20%
12:00PM	Loading…
May-29-25 12:00PM	Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +13.46%
09:55AM	Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade (Zacks)
May-23-25 07:00AM	Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago (GlobeNewswire) -14.59%
May-22-25 06:00AM	Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025 (GlobeNewswire) +51.73%
May-13-25 07:00AM	Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.87%
Apr-14-25 05:57AM	Here's Why Summit Therapeutics Stock Soared 15% on Friday (Zacks) +11.78%
Mar-04-25 07:09AM	Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-02-25 06:15AM	Jefferies Predicts Up to ~500% Jump for These 2 Strong Buy Stocks (TipRanks)
Jan-14-25 07:00AM	Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody (GlobeNewswire) +5.31%
Nov-13-24 07:00AM	Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.51%
Oct-23-24 01:01AM	Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc (GuruFocus.com) -5.27%
Sep-27-24 09:43PM	BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc (GuruFocus.com)
07:03PM	Perceptive Advisors LLC Acquires New Stake in Instil Bio Inc (GuruFocus.com)
Sep-25-24 04:56AM	2 Stocks Up Over 700% in 2024 That Could Soar Even Further (Motley Fool)
Sep-17-24 04:24AM	Here's Why Everyone's Talking About Summit Therapeutics (Motley Fool)
06:00AM	Loading…
Sep-16-24 06:00AM	Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer (GlobeNewswire) -23.91%
Sep-14-24 04:56AM	Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? (Motley Fool)
Aug-13-24 10:53PM	TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024 (InvestorPlace)
05:00PM	Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-24 06:00AM	Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody (GlobeNewswire)
Jul-12-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +31.13%
May-10-24 01:54PM	TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-27-24 12:00PM	What Makes Instil Bio (TIL) a New Buy Stock (Zacks)
Mar-21-24 10:52PM	TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023 (InvestorPlace)
05:00PM	Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-18-24 12:28PM	Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why (Zacks) +6.49%
Jan-16-24 08:00AM	Instil Bio Announces Strategic Update (GlobeNewswire)
Dec-13-23 10:52AM	TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023 (InvestorPlace)
10:51AM	TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023 (InvestorPlace)
Dec-05-23 05:00PM	Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split (GlobeNewswire)
Nov-13-23 05:00PM	Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.42%
Nov-06-23 07:00AM	Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting (GlobeNewswire)
Aug-31-23 09:35AM	After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL) (Zacks)
Aug-14-23 07:00AM	Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.18%
Jun-26-23 04:38PM	Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference (GlobeNewswire)
May-11-23 07:00AM	Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -7.42%
Mar-31-23 07:00AM	Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-22-23 07:57AM	Heres Why Instil Bio (TIL) Declined in Q4 (Insider Monkey) -5.57%
Feb-17-23 07:04AM	Private equity firms account for 39% of Instil Bio, Inc.'s (NASDAQ:TIL) ownership, while institutions account for 34% (Simply Wall St.)
Jan-31-23 05:00PM	Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site (GlobeNewswire) +6.52%
Jan-09-23 12:30PM	Instil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal Cancers (Benzinga) +5.73%
07:00AM	Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer (GlobeNewswire)
Dec-13-22 09:35AM	Down 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL) (Zacks) -16.25%
Dec-09-22 09:35AM	Down 59.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL) (Zacks)
Dec-08-22 11:04AM	Instil Bio Discontinues ITIL-168 Cancer Trials, Layoffs 60% Of Its Employees (Benzinga) -19.67%
07:00AM	Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce (GlobeNewswire)
Nov-14-22 04:07PM	Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.74%
Nov-08-22 07:00AM	Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-31-22 10:40AM	Instil Bio Share Sink After Enrollment Pause In Cancer Therapy Trials (Benzinga) -37.14%
08:52AM	Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials (MarketWatch)
07:00AM	Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing (GlobeNewswire)
Oct-18-22 07:00AM	Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FR), in Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-19-22 07:20AM	Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit (GlobeNewswire) -7.07%
Sep-09-22 07:00AM	Instil Bio to Present at Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Sep-06-22 07:00AM	Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer (GlobeNewswire)
Aug-12-22 07:00AM	Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-12-22 08:21AM	Will Instil Bio (NASDAQ:TIL) Spend Its Cash Wisely? (Simply Wall St.)
Jul-11-22 05:28PM	Instil Bio Life Sciences Campus in Tarzana gets $85 million loan for expansion (American City Business Journals) -6.27%
May-27-22 07:00AM	Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment (GlobeNewswire) -24.34%
May-18-22 07:00AM	Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire) -5.09%
May-16-22 07:00AM	Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +8.70%
Mar-07-22 07:00AM	Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-02-22 07:00AM	Instil Bio to Present at the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Nov-15-21 07:00AM	Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-10-21 11:28AM	Was The Smart Money Right About Instil Bio, Inc. (TIL)? (Insider Monkey)
Nov-08-21 08:05AM	Instil Bio to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Sep-16-21 07:00AM	Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress (GlobeNewswire)
Sep-15-21 04:27PM	Why Iovance Is Up Nearly 11% Today (Motley Fool) +16.55%
Sep-13-21 07:00AM	Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma (GlobeNewswire)
Sep-02-21 07:00AM	Instil Bio to Present at Upcoming Investor Conferences in September (GlobeNewswire) +7.49%
Aug-12-21 07:00AM	Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-19-21 02:34PM	Do Hedge Funds Love Instil Bio, Inc. (TIL)? (Insider Monkey)
Jun-21-21 10:06AM	Are Institutions Heavily Invested In Instil Bio, Inc.'s (NASDAQ:TIL) Shares? (Simply Wall St.)
Jun-01-21 07:00AM	Instil Bio to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-13-21 07:00AM	Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.83%
Apr-29-21 08:45AM	At a Recent Cancer Research Conference, Instil Bio Stole the Show (Motley Fool) +6.10%
Apr-27-21 07:00AM	Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma (GlobeNewswire)
Apr-12-21 07:18AM	Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-23-21 05:00PM	Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -6.95%
Mar-19-21 04:25PM	Three Biotechs, plus a Marijuana Lender, Open for Trading (Barrons.com)
Mar-18-21 08:26PM	Instil Bio Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Instil Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Chairman & CEOMr. Bronson Crouch

CFO & Chief Business OfficerDr. Sandeep Laumas M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Laumas Sandeep	CFO and CBO	Sep 10 '25	Option Exercise	12.07	30,000	362,040	30,000	Sep 12 05:00 PM
Laumas Sandeep	CFO and CBO	Sep 10 '25	Sale	23.39	30,000	701,667	0	Sep 12 05:00 PM
SANDEEP LAUMAS	Officer	Sep 10 '25	Proposed Sale	23.39	30,000	701,595		Sep 10 05:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TIL

Instil Bio Inc

Upgrade your Finviz experience